Endologix acquires PQ Bypass

Endologix LLC, a firm specializing in vascular disease treatments, has completed the acquisition of PQ Bypass Inc., a privately held medical technology company pioneering a technology that addresses an unmet need for new treatments for severe peripheral arterial disease .

PQ Bypass’ proprietary Detour platform for percutaneous femoral-popliteal bypass was designated by the U.S. Food & Drug Administration as a Breakthrough Device. The Detour System consists of the TORUS stent graft and the PQ Crossing Device. It is currently being studied in a U.S. and European clinical trial, DETOUR2.

“The acquisition of PQ Bypass is a seminal moment in Endologix’s history, building upon our leadership in the treatment of abdominal aortic aneurysm to champion disruptive technologies for the treatment of vascular disease,” Richard Mott, CEO and chairman, Endologix told the press. “We intend to actively pursue new and innovative vascular technologies that are clinically relevant to surgeons, hospitals and patients, with a commitment to world-class medical education, clinical research and excellent procedural outcomes.”

Andrew ElBardissi, M.D., partner at Deerfield Management, stated, “We are excited about the progress that Endologix has made over the past year. With the acquisition of PQ Bypass, we believe the company is positioned to accelerate its leadership in the treatment of vascular disease. MPO Mag